Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cryptococcosis - Overview
Cryptococcosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cryptococcosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cryptococcosis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals Inc
Amtixbio Co Ltd
Basilea Pharmaceutica Ltd
Collaborations Pharmaceuticals Inc
iNtRON Biotechnology Inc
Mycovia Pharmaceuticals Inc
Novabiotics Ltd
Pulmocide Ltd
Visterra Inc
Cryptococcosis - Drug Profiles
APX-2039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Cryptococcosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cryptococcosis - Dormant Projects
Cryptococcosis - Discontinued Products
Cryptococcosis - Product Development Milestones
Featured News & Press Releases
Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications
Feb 11, 2019: FDA grants orphan drug desigtion to Amplyx Pharmaceuticals for APX001 for treatment of cryptococcosis
Apr 18, 2018: Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavucozole
Mar 12, 2018: Amplyx Pharmaceuticals Receives Fourth Qualified Infectious Disease Product Desigtion from the FDA for APX001
Jun 27, 2016: New Promise Against Deadly Global Fungal Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Cryptococcosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Cryptococcosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cryptococcosis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2020
Cryptococcosis - Pipeline by Amtixbio Co Ltd, H2 2020
Cryptococcosis - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
Cryptococcosis - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Cryptococcosis - Pipeline by iNtRON Biotechnology Inc, H2 2020
Cryptococcosis - Pipeline by Mycovia Pharmaceuticals Inc, H2 2020
Cryptococcosis - Pipeline by Novabiotics Ltd, H2 2020
Cryptococcosis - Pipeline by Pulmocide Ltd, H2 2020
Cryptococcosis - Pipeline by Visterra Inc, H2 2020
Cryptococcosis - Dormant Projects, H2 2020
Cryptococcosis - Discontinued Products, H2 2020